Methylcobalamin ULTRA is an ultra-high dose formulation of methylcobalamin, the neurologically active coenzyme form of vitamin B12. Methylcobalamin supports the healthy structure and functioning of the brain and nervous system. Studies show that a person may not have optimal methylcobalamin for proper neurological function, even when vitamin B12 intake and status is normal. This higher-dose formulation is for persons for whom research supports supplementation at higher levels than in our standard Methylcobalamin formulation.
Methylcobalamin is the coenzyme form of vitamin B12 which supports the healthy structure and function of the nerves and brain. Several studies have found that people can have neurological signs and symptoms of a specific Methylcobalamin deficiency, even when serum B12, and blood tests which measure adenosylcobalamin acitivity, are perfectly normal. This is in large part because, while the body can store adenosylcobalamin (the other coenzyme form of vitamin B12) in the liver and mitochondria, Methylcobalamin is located in fluids like the cerebrospinal fluid and plasma, and is urinated out rather than stored.
While healthy people need just a tiny trace of Methylcobalamin to avoid a frank deficiency, a massive body of evidence powerfully supports the conclusion that supplementing with megadose levels of Methylcobalamin - and not regular B12 - can protect brain and nerve cells against toxins, help the healing of damaged neurons, and even provide powerful nutritional support in neurodegenerative diseases.
Paralyzing Viruses Several groups of scientists have investigated the use of Methylcobalamin in Bell's palsy, and they have uniformly found that Methylcobalamin speeds the recovery of normal nerve function. In two separate human trials, patients were given either prednisone alone (a steroid anti-inflammatory drug commonly used to treat Bell's palsy), Methylcobalamin alone, or the drug and the coenzyme together. Both trials found that the time required for complete recovery was significantly shorter for people who took Methylcobalamin (whether in combination with prednisone, or even by itself) than for those who took the steroid drug alone.
Multiple Sclerosis (MS )In a pilot trial, six people with degenerating MS received 60 milligrams of Methylcobalamin a day. The scientists compared the changes which took place in the patients' nerve function over the course of up to two years before the trial began, to the changes which happened during the six months in which the patients took Methylcobalamin. They found that there was a significant improvement in nerve function while patients took Methylcobalamin. Before Methylcobalamin, about one fifth of all measurements of nerve function suggested that the nerves were degenerating. While the patients were supplementing with Methylcobalamin, however, only half as many nerve measurements showed signs of degeneration. And while, in the time before the trial began, just 4% of the nerve measurements suggested that the nerve in question had improved, it was found that 18%, or four-and-a-half times as many nerve readings, showed signs of improvement while patients were taking Methylcobalamin.
Lou Gehrig's Disease In a randomized, double-blind, controlled trial, 24 patients with Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig's disease, took megadoses of Methylcobalamin through intramuscular injection for just under a month at one of two doses (25 milligrams or 500 micrograms a day). While no results were seen in the lower dose, patients who took the higher dose of Methylcobalamin experienced increases in measurements of their nerves' ability to trigger responses in the muscles. Two patients' gaits were also noted to improve in the higher-dose group.
Alzheimer's Disease Two trials have between them found that giving Methylcobalamin to people with Alzheimer's disease or related dementias (like Pick's disease) leads patients to have better interaction with other people and with the world around them, while improving mood and relieving neurological symptoms. The evaluation by the patients' familes and physicians was also improved. The findings in these trials on intellectual functioning were inconsistent: some scales showed improvements, but others did not. Both of these trials, however, used relatively low doses of Methylcobalamin.
A Good Guess: Parkinson's Disease There's good reason to believe that Parkinson's disease is caused and/or accelerated by "excitotoxicity" resulting from overstimulation by the neurotransmitter glutamate. Drugs which lower glutamate levels, or which "tune down" its receptor, improve many of the symptoms of the disease, while drugs which stimulate the receptor make them worse.
So if Methylcobalamin protects neurons from the toxicity of glutamate, might it provide support for people with Parkinson's disease? Unfortunately, no clinical trials have yet been run to test this idea. But granted how safe Methylcobalamin supplements have proven to be, and its clear benefits in other neurodegenerative diseases, this essential coenzyme holds out hope as a potential way to prevent, and perhaps even to treat, this debilitating disease.
Caramelized Nerves A string of clinical trials have reported that Methylcobalamin improves nerve function in people with diabetic neuropathy as demonstrated by things like improvements in the ability to detect gentle vibration, reduced tingling, numbness, and pain in the extremities, less feelings of "heaviness" in the legs, and the restoration of neurons' ability to efficiently transmit a signal and to properly regulate the heartbeat. Trials which have looked at the overall improvement of patients' neuropathic symptoms and signs have also reported remarkably positive results.
Eyes Under Pressure In a controlled study, 14 patients with normal-tension glaucoma were treated with Methylcobalamin, and their progress was compared with that of 22 other normal-tension glaucoma patients who did not take Methylcobalamin supplements. While 59% of the people not taking Methylcobalamin experienced worsening sight, 86% of patients taking Methylcobalamin experienced no loss of function.
The Squeezing Spine Lumbar spinal stenosis is the compression of the nerves in the lower spine caused by arthritis, spinal degeneration, injury, or sometimes unfortunate genes. The squeezing of the nerves leads to pain on exertion in the lower back or buttocks, which is relieved by shifting position. In a single-blind, randomized controlled trial, 152 people with lumbar spinal stenosis were given the current standard care (physiotherapy, standard drugs, and education on managing their disease), and additionally either did or did not take Methylcobalamin. For whatever reason, the dose chosen for the trial was very low (half a milligram) compared to what has been used successfully in most trials pitting Methylcobalamin against nerve disease. At this low dose, there was no improvement in pain or in the doctors' evaluations of the appearance, sensation, or function of their nerves; however, despite the clearly inadequate dose, those people who took Methylcobalamin found themselves able to walk further distances without experiencing pains than people who were not taking it.
The Question of Dose In general, most trials in which Methylcobalamin has been used to help people with various forms of diabetic neuropathy, non-diabetic neuropathy associated with uremia, peripheral facial paralysis (including Bell's palsy and Ramsay Hunt Syndrome), normal tension glaucoma and dementia (including Pick's disease and Alzheimer's disease) have used doses ranging from1.5 to 5 milligrams. On the other hand, trials involving victims of ALS (Lou Gehrig's disease) and multiple sclerosis (MS) have used much higher doses, such as 25 milligrams per day for ALS and 60 milligrams daily for MS.
Note that in some cases only one trial has ever been performed, with only a single dose used, and the results are often preliminary; it's therefore possible that higher (or lower) doses might be more effective. Because of the well-established safety of Methylcobalamin, many nutritionally-oriented physicians are working with their patients using doses considerably higher than those used in the relevant trial. There are some cases where this has seemed especially prudent to some physicians.
For instance, the evidence suggests that Methylcobalamin is much more effective against Bell's Palsy when taken within days of the initial attack; at later times, a higher dose might be more appropriate. Likewise, the only trial of Methylcobalamin in patients with lumbar spinal stenosis used only 0.5 milligrams per day - and achieved only very minor results. It seems reasonable to speculate that a higher dose might have been more effective, granted the fact that nearly all successful trials in other neurological disorders have used minimum doses of 1.5 milligrams, and many have been higher. Discuss these issues with your doctor.
There are also several neurological disorders in which there is reason to believe that Methylcobalaminmight make a good supplement choice if your physician approves, but in which no clinical trial has been performed. These would include Parkinson's disease, tinnitus, Spinal Muscular Atrophy (SMA), and people suffering with environmental illnesses who suffer with neurological signs and symptoms. In such cases, because we don't have formal human trials to use as a guideline, your physician will have to rely all the more strongly on his or her judgement.
A range of Methylcobalamin sublingual supplements are now available, making customizing your dose more convenient and affordable than at any time in the past.
METHYLCOBALAMIN ULTRA
60 Lozenge
______________________________________________
SUPPLEMENT FACTS:
Serving Size: 1 Lozenge %DRI______________________________________________
Methylcobalamin ......................... 15 mg *
_______________________________________________
*Dietary Reference Intake not established.
Other ingredients: sorbitol, fructose, natural cherry, magnesium stearate, citric acid, stearic acid.
AOR guarantees that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, dairy, soy, eggs, fish or shellfish.
Suggested Use
Dissolve one to three tablets under the tongue in the morning, or as directed by a qualified health consultant.
Main Applications
As reported by literature:
Neuroprotection.
Nutritonal support in neurological disorders.
Source
Pharmaceutical synthesis.
Pregnancy / Nursing
Safe at one half of one tablet daily.
Cautions
None known.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
PRE 0.24 
POST 13.05 
Serving Size
